当前位置: X-MOL 学术Diabetes Obes. Metab. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double‐blind, placebo‐controlled, phase 3 trial
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2021-01-08 , DOI: 10.1111/dom.14314
Juming Lu 1 , Liujun Fu 2 , Yan Li 3 , Jianlin Geng 4 , Li Qin 5 , Li Ping 6 , Hailong Zheng 7 , Zilin Sun 8 , Yanbing Li 9 , Lihui Zhang 10 , Yadong Sun 11 , Daoxiong Chen 12 , Guijun Qin 13 , Lu Weiping 14 , Yushan Guo 15 , Yuwei Zhang 16 , Haiyan Liu 17 , Tao Zhang 17 , Jianjun Zou 17
Affiliation  

To evaluate henagliflozin, a novel sodium‐glucose co‐transporter‐2 inhibitor, as monotherapy in patients with type 2 diabetes and inadequate glycaemic control with diet and exercise.

中文翻译:

Henagliflozin单一疗法对饮食和运动控制不佳的2型糖尿病患者:一项随机,双盲,安慰剂对照的3期临床试验

评估一种新型的钠-葡萄糖共转运蛋白2抑制剂henagliflozin作为2型糖尿病患者的单药治疗,以及饮食和运动对血糖的控制不足。
更新日期:2021-01-08
down
wechat
bug